Skip to main content

Table 2 Participant characteristics and PPH outcomes among Ecuadorian women given PPH treatment with sublingual misoprostol (600mcg and 800mcg)*

From: Dose and side effects of sublingual misoprostol for treatment of postpartum hemorrhage: what difference do they make?

  600 mcg(n = 50) 800 mcg(n = 163)
Baseline characteristics
Age (yr) mean ± sd, 23 ± 6 24 ± 6
   Range 14 – 41 14 – 42
Currently married 39 (78.0) 140 (85.3)
   No education 0 (0.0) 0 (0.0)
   Primary 11 (22.0) 50 (30.7)
   Secondary 29 (58.0) 96 (58.9)
   University or higher 10 (20.0) 14 (8.6)
   0 27 (54.0) 65 (39.9)
   1–3 21 (42.0) 86 (52.8)
   4+ 2 (4.0) 12 (7.3)
Pre-delivery Hb mean ± sd, 13.4 ± 1.4 13.5 ± 1.3
   Range 10.1 – 18.1 10.3 – 16.9
   Pre–term (less than 37) 2 (4.0) 6 (3.7)
   Term (37·0 – 40·9) 42 (84.0) 137 (84.0)
   Post–term (41 or more) 6 (12.0) 20 (12.3)
Multiple pregnancy 0 (0) 0 (0)
Known previous PPH 1 (2.0) 8 (4.9)
Delivery characteristics
Labor induced/augmented 34 (68.0) --
Oxytocin given in 3rd stage of labor 50 (100.0) --
Controlled cord traction + 45 (90.0) 114 (69.9)
Uterine massage + 50 (100.0) 131 (80.4)
PPH outcomes
Blood loss (mL) at time of treatment median (IQR) 850 (750,1050) 850 (750, 1000)
Total blood loss (mL) median (IQR)+ 1000 (850, 1200) 1150 (950, 1400)
Blood loss ≥500 mL post-treatment 5 (10.0) 29 (17.8)
Blood loss ≥1000 mL post-treatment 0 (0.0) 3 (6.0)
Post-treatment Hb median IQR ^+ 10.8 (9.9, 11.4) 9.9 (8.9, 11.0)
Difference between pre/post Hb median IQR^+ 2.6 (1.4, 4.0) 3.5 (2.6, 4.8)
Drop in Hb ≥ 2 g/dL ^+ 31 (63.3) 131 (85.6)
Additional uterotonics + 9 (18.0) 12 (7.4)
Blood transfusion 1 (2.0) 10 (6.1)
Exploration under anesthesia 9 (18.0) 16 (9.8)
  1. * Values are given as n (%) unless stated otherwise.
  2. ^ Post-delivery hemoglobins available for 49 women in the 600mcg study and 153 women in 800mcg study.
  3. + P ≤ 0.05.